TransCode Therapeutics, Inc. (RNAZ)
$1.68+3.07%Close
SELLCRISIS · day 2
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $2M
- Beta
- 1.26
- P/E (TTM)
- -0.03
- Short % float
- 6.01%
- Days to cover
- 1.0
- SI change
- -15.2%
- 1W
- -5.62%
- 1M
- +1.82%
- vs SPY 1W
- -5.48%
- vs SPY 1M
- -0.69%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 10
- VALUE
- 13
- GROWTH
- 45
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-34.8%
REV YoY-
ROE-58.1%
EPS YoY-
ROA-28.3%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.03
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B0.01
P/FCF-
EV/EBITDA0.14
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.47
ALTMAN Z-
CURR RATIO1.97
ND/EBITDA-
BETA1.26
Company news
FAQ
- What is LOPJLB’s current signal on RNAZ?
- LOPJLB’s latest quantitative signal on TransCode Therapeutics, Inc. (RNAZ) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is RNAZ in?
- TransCode Therapeutics, Inc. (RNAZ) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does TransCode Therapeutics, Inc. (RNAZ) do?
- TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidat…